HEPLISAV-B

This brand name is authorized in Estonia, Croatia, Ireland, Lithuania, Poland, United States

Active ingredients

The drug HEPLISAV-B contains one active pharmaceutical ingredient (API):

1 Hepatitis B, purified antigen UNII XL4HLC6JH6 - HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. Read about Hepatitis B, purified antigen

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HEPLISAV B Solution for injection in pre-filled syringe	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BC01	Hepatitis B, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1842858
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092062
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100448789
Country: US	FDA, National Drug Code	Identifier(s): 43528-003